A comparative evaluation of properties and clinical efficacy of the echinocandins

Bibliography

• DENNING DW: Echinocandin antifungal drugs. Lancet (2003) 362:1142-1151.
   PubMed Web of Science ®Google Scholar
• MORRIS MI, VILLMANN M: Echinocandins in the management of invasive fungal infections, part 1. Am. J. Health-Syst. Pharm. (2006) 63:1693-1703.
   PubMed Web of Science ®Google Scholar
• THEURETZBACHER U: Pharmacokinetics/pharmacodynamics of echinocandins. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:805-812.
   PubMed Web of Science ®Google Scholar
• MERCK AND CO: Cancidas (caspofungin acetate for intravenous injection). Prescribing information (February 2005).
   Google Scholar
• ASTELLAS PHARMA US: Mycamine (micafungin sodium for injection). Prescribing information (June 2006).
   Google Scholar
• PFIZER INC.: Eraxis (anidulafungin for injection). Prescribing information (March 2006).
   Google Scholar
• MCCORMACK PL, PERRY CM: Caspofungin. A review of its use in the treatment of fungal infections. Drugs (2005) 65:2049-2068.
   PubMed Web of Science ®Google Scholar
• MURDOCH D, PLOSKER GL: Anidulafungin. Drugs (2004) 64:2249-2258.
   PubMed Web of Science ®Google Scholar
• LOUIE A, DEZIEL M, LIU W et al.: Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. (2005) 63:5058-5068.
   Google Scholar
• ANDES D: Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. North Am. (2006) 20:679-697.
   PubMed Web of Science ®Google Scholar
• WIEDERHOLD NP, KONTOYIANNIS DP, CHI J et al.: Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. (2004) 190:1464-1471.
   PubMed Web of Science ®Google Scholar
• OSTROSKY-ZEICHNER L, REX JH, PAPPAS PG et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. (2003) 47:3149-3154.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. (2003) 20:121-136.
   PubMedGoogle Scholar
• ZAAS AK, ALEXANDER BD: Echinocandins: role in antifungal therapy, 2005. Expert Opin. Pharmacother. (2005) 6:1657-1688.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, BOYKEN L, HOLLIS RJ et al.: In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. (2006) 44:760-763.
   PubMed Web of Science ®Google Scholar
• KROGH-MADSEN M, ARENDRUP MC, HESLET L et al.: Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. (2006) 42:938-944.
   PubMed Web of Science ®Google Scholar
• LAVERDIERE M, LALONDE RG, BARIL JG et al.: Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. (2006) 57:705-708.
   PubMed Web of Science ®Google Scholar
• PARK S, KELLY R, KAHN JN et al.: Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob. Agents Chemother. (2005) 49:3264-3273.
   PubMed Web of Science ®Google Scholar
• STONE JA, MIGOYA EM, HICKEY L et al.: Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. (2004) 48:4306-4314.
   PubMed Web of Science ®Google Scholar
• HEBERT MF, BLOUGH DK, TOWNSEND RW et al.: Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. (2005) 45:1018-1024.
   PubMed Web of Science ®Google Scholar
• HEBERT MF, TOWNSEND RW, AUSTIN S et al.: Concomitant ciclosporin and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. (2005) 45:954-960.
   PubMed Web of Science ®Google Scholar
• DOWELL JA, STOGNIEW M, KRAUSE D et al.: Assessment of the safety and pharmacokinetics of anidulafungin when administered with ciclosporin. J. Clin. Pharmacol. (2005) 45:227-233.
   PubMed Web of Science ®Google Scholar
• SANZ-RODRIGUEZ C, ARRANZ R, CISNEROS JM et al.: Absence of clinically relevant effect of caspofungin on cyclosporin pharmacokinetics. Swiss Med. Wkly. (2005) 135:658-659.
   PubMed Web of Science ®Google Scholar
• MARR KA, HACHEM R, PAPANICOLAOU G et al.: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl. Infect. Dis. (2004) 6:110-116.
   PubMedGoogle Scholar
• RUHNKE M: Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005):M-722c.
   Google Scholar
• VILLANUEVA A, ARATHOON EG, GOTTUZZO E, BERMAN RS, DINUBILE MJ, SABLE CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. (2003) 33:1529-1535.
   Google Scholar
• ARATHOON EG, GOTUZZO E, NORIEGA LM, BERMAN RS, DINUBILE MJ, SABLE CA: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. (2002) 46:451-457.
   PubMed Web of Science ®Google Scholar
• VILLANUEVA A, GOTTUZZO E, ARATHOON EG et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. (2002) 113:294-299.
   PubMed Web of Science ®Google Scholar
• KARTSONIS N, DINUBILE MJ, BARTIZAL K, HICKS PS, RYAN D, SABLE CA: Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immune. Defic. Syndr. (2002) 31:183-187.
   PubMed Web of Science ®Google Scholar
• VEROUX M, MACARONE M, FIAMINGO P et al.: Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant receipients. Transplant. Proc. (2006) 38:1037-1039.
   PubMedGoogle Scholar
• PETTENGELL K, MYNHARDT J, KLUYTS T, LAU W, FACKLAM D, BUELL D: Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment. Pharmacol. Ther. (2004) 20:475-481.
   PubMed Web of Science ®Google Scholar
• DE WET N, LLANOS-CUENTAS A, SULEIMAN J et al.: A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. (2004) 39:842-849.
   PubMed Web of Science ®Google Scholar
• DE WET NT, BESTER AJ, VILJOEN JJ et al.: A randomized, double blind, comparative trial of micafungin (FK463) versus fluconazole for the treatment of oesophageal candidiasis. Aliment. Pharmacol. Ther. (2005) 21:899-907.
   PubMed Web of Science ®Google Scholar
• KOHNO S, MASAOKA T, YAMAGUCHI H et al.: A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand. J. Infect. Dis. (2004) 36:372-379.
   PubMed Web of Science ®Google Scholar
• ERNST EJ, ROLING EE, PETZOLD CR, KEELE DJ, KLEPSER ME: In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. (2002) 46:3846.
   PubMed Web of Science ®Google Scholar
• BUELL D, KOVANDA L, DRAKE T, FISCO C: Alternative day dosing of micafungin in the treatment of esophageal candidiasis. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005):M-719.
   Google Scholar
• KRAUSE DS, SIMJEE AE, VAN RENSBURG C et al.: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. (2004) 39:770-775.
   PubMed Web of Science ®Google Scholar
• KELLEY K, CHAPMAN S, CLEARY JD: Digestion of echinocandins. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005):M-366.
   Google Scholar
• VASQUEZ J, SCHRANZ JA, KRAUSE D et al.: Efficacy of anidulafungin (ANID) in patients (Pts) with azole-refractory candidiasis (ARMC). Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (2004):M-1038.
   Google Scholar
• REX JH, WALSH TJ, ANAISSIE EJ: Fungal infections in iatrogenically compromised hosts. Adv. Intern. Med. (1998) 43:321-371.
   PubMedGoogle Scholar
• WISPLINGHOFF H, BISCHOFF T, TALLENT SM, SEIFERT H, WENZEL RP, EDMOND MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. (2004) 39:309-317.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, DIEKEMA DJ: Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. (2004) 10(Suppl. 1):11-23.
   PubMed Web of Science ®Google Scholar
• PAPPAS PG, REX JH, SOBEL JD et al.: Guidelines for treatment of candidiasis. Clin. Infect. Dis. (2004) 38:161-189.
   PubMed Web of Science ®Google Scholar
• MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347:2020-2029.
   PubMed Web of Science ®Google Scholar
• REBOLI A, ROTSTEIN C, PAPPAS P et al.: Anidulafungin versus fluconazole for the treatment of candidemia and invasive candidiasis (C/IC). Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. (2005):M-718.
   Google Scholar
• KRAUSE DS, REINHARDT J, VAZQUEZ JA et al.: Phase II, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. (2004) 48:2021-2024.
   PubMed Web of Science ®Google Scholar
• OSTROSKY-ZEICHNER L, KONTOYIANNIS D, RAFFALLI J et al.: International open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24:654-661.
   PubMed Web of Science ®Google Scholar
• STEVENS DA, MCCULLOUGH MJ, CLEMONS KV, MARTINEZ MC: Candida dubliniensis (Cd), a species with an extremely high frequency of paradoxical effect (PE) with caspofungin (CAS). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-1756.
   Google Scholar
• STEVENS DA, ICHINOMIYA M, KOSHI Y, HORIUCHI H: Escape of Candida from caspofungin inhibition at supra-MIC concentrations (‘paradoxical effect’) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-363.
   Google Scholar
• BETTS RF, ROTSTEIN C, TALWAR D et al.: Comparison of micafungin and caspofungin for candidemia or invasive candidiasis (IC). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-1308a.
   Google Scholar
• CORNELY O, LASSO M, BETTS R et al.: Prospective, multicenter study of caspofungin (CAS) for treatment (Rx) of less common forms of invasive candidiasis (IC). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-893.
   Google Scholar
• VAN BURIK JA, RATANATHARATHORN V, STEPAN DE et al.: Micafungin versus fluconazole for prophylaxis against fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. (2004) 39:1407-1416.
   PubMed Web of Science ®Google Scholar
• MATTIUZZI GN, ALVARADO G, GILES FJ et al.: Open-labeled, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic mailignancies. Antimicrob. Agents Chemother. (2006) 50:143-147.
   PubMed Web of Science ®Google Scholar
• FORTUN J, MUNOZ P, MARTIN-DAVILA P et al.: Prospective, multicenter study of caspofungin (CAS) for prophylaxis in high risk liver transplantation (LT). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):K-272.
   Google Scholar
• WALSH TJ, TEPPLER H, DONOWITZ GR et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. (2004) 351:1391-1402.
   PubMed Web of Science ®Google Scholar
• MARR KA, CARTER RA, CRIPPA F, WALD A, COREY L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. (2002) 34:909-917.
   PubMed Web of Science ®Google Scholar
• MORGAN J, WANNEMUEHLER KA, MARR KA et al.: Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. (2005) 43(Suppl. 1):S49-S58.
   PubMed Web of Science ®Google Scholar
• LIN SJ, SCHRANZ J, TEUTSCH SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. (2001) 32:358-366.
   PubMed Web of Science ®Google Scholar
• KARTSONIS NA, SAAH AJ, LIPKA CJ, TAYLOR AF, SABLE CA: Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J. Infect. (2005) 50:196-205.
   PubMed Web of Science ®Google Scholar
• MAERTENS J, RAAD I, PETRIKKOS G et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. (2004) 39:1563-1571.
   PubMed Web of Science ®Google Scholar
• GLASMACHER A, CORNELY OA, ORLOPP K et al.: Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J. Antimicrob. Chemother. (2006) 57:127-134.
   PubMed Web of Science ®Google Scholar
• BETTS R, GLASMACHER A, MAERTENS J et al.: Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer (2005) 106:466-473.
   Google Scholar
• CANDONI A, MESTRONI R, DAMIANI D et al.: Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur. J. Haematol. (2005) 75:227-233.
   PubMed Web of Science ®Google Scholar
• JAFRI H, ZAOUTIS T, KELLER N et al.: Prospective, multicenter study of caspofungin (CAS) for treatment (Rx) of documented fungal infections in pediatric patients (Ped Pts). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):G-873a.
   Google Scholar
• DENNING DW, MARR KA, LAU WM et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for treatment of acute invasive aspergillosis. J. Infect. (2006) 53:337-349.
   PubMed Web of Science ®Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. (2002) 46:245-247.
   PubMed Web of Science ®Google Scholar
• PEREA S, GONZALEZ G, FOTHERGILL AW, KIRKPATRICK WR, RINALDI MG, PATTERSON TF: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. (2002) 46:3039-3041.
   PubMed Web of Science ®Google Scholar
• SHALIT I, SHADKCHAN Y, SAMRA Z, OSHEROV N: In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob. Agents Chemother. (2003) 47:1416-1418.
   PubMed Web of Science ®Google Scholar
• MANAVATHU EK, ALANGADEN GJ, CHANDRASEKAR PH: Differential activity of triazoles in two-combinations with the echinocandin caspofungin against Aspergillus fumigatus. J. Antimicrob. Chemother. (2003) 51:1423-1425.
   PubMed Web of Science ®Google Scholar
• SIONOV E, MENDLOVIC S, SEGAL E: Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J. Infect. (2006) 53:131-139.
   PubMed Web of Science ®Google Scholar
• MACCALLUM DM, WHYTE JA, ODDS FC: Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob. Agents Chemother. (2005) 49:3697-3701.
   PubMed Web of Science ®Google Scholar
• LUQUE JC, CLEMONS KV, STEVENS DA: Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob. Agents Chemother. (2003) 47:1452-1455.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, BOCANEGRA R, GONZALEZ GM, NAJVAR LK: Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J. Antimicrob. Chemother. (2003) 52:656-662.
   PubMed Web of Science ®Google Scholar
• PETRAITIS V, PETRATIENE R, HOPE W et al.: Combination therapy of voriconazole and anidulafungin improves outcome of experimental pulmonary aspergillosis. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-882.
   Google Scholar
• ALIFF TB, MASLAK PG, JURCIC JG et al.: Refractory aspergillus pneumonia in patients with acute leukemia. Cancer (2003) 97:1025-1032.
   PubMed Web of Science ®Google Scholar
• KONTOYIANNIS DP, HACHEM R, LEWIS RE et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer (2003) 98:292-299.
   PubMed Web of Science ®Google Scholar
• MARR KA, BOECKH M, CARTER RA, KIM HW, COREY L: Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. (2004) 39:797-802.
   PubMed Web of Science ®Google Scholar
• SINGH N, LIMAYE AP, FORREST G et al.: Combination of voriconazole and caspofungin as primary therapy of invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 81:320-326.
   PubMed Web of Science ®Google Scholar
• KONTOYIANNIS DP, RATANATHARATHORN V, VAN BURIK J et al.: Micafungin (MCF) alone or in combination with other licensed antifungal agent (OLAT) in bone marrow transplant (BMT) recipients with invasive aspergillosis (IA). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-878.
   Google Scholar
• FLYNN PM, SEIBEL N, ARRIETA A et al.: Treatment of invasive aspergillosis (IA) in pediatric patients (Pts) with micafungin (MICA) alone or in combination with other systemic antifungal agents. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-891.
   Google Scholar
• REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. (1994) 331:1325-1330.
   PubMed Web of Science ®Google Scholar
• REX JH, PAPPAS PG, KARCHMER AW et al.: A randomized and blinded multicenter trial of high dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic patients. Clin. Infect. Dis. (2003) 36:1221-1228.
   PubMed Web of Science ®Google Scholar
• KULLBERG BJ, SOBEL JD, RUHNKE M et al.: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet (2005) 366:1435-1442.
   PubMed Web of Science ®Google Scholar